A Phase I, Open-label, Multi-center, Randomized, Crossover Study to Assess the Bioequivalence of 2 Formulations of TKI258, FMI Capsule and FMI Tablet, in Patients With Advanced Solid Tumors

Inclusion Criteria:

1. Patients with a histopathologically or cytopathologically confirmed diagnosis of an
advanced solid tumor, excluding breast cancer, who have progressed despite standard
therapy, or for which no standard therapy exists

2. ECOG performance status (PS) 0, 1 or 2

3. Patients must meet protocol-specified laboratory values

Exclusion Criteria:

1. Patients with brain metastases

2. Patients who have concurrent severe and/or uncontrolled medical conditions which
could compromise participation in the study

3. Patients who have not recovered from previous anti-cancer therapies

4. Patients who are expected to receive any prohibited medications during the
bioequivalence phase of the study

5. Female patients who are pregnant, breast feeding

6. Fertile male or women of child-bearing potential not willing to use two highly
effective methods of contraception

Other protocol-defined inclusion/exclusion criteria may apply